Related references
Note: Only part of the references are listed.Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre
Juan Ambrosioni et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
Paul E. Sax et al.
CLINICAL INFECTIOUS DISEASES (2021)
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
Charlotte-Paige Rolle et al.
MEDICINE (2021)
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV
Jordan E. Lake et al.
CURRENT OPINION IN HIV AND AIDS (2021)
Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naive and Switch Scenarios in HIV-Infected Patients
Maria Saumoy et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy
Nicholas Chamberlain et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy
Rachel N. Goldberg et al.
JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE (2021)
Understanding the Risk of Human Immunodeficiency Virus (HIV) Virologic Failure in the Era of Undetectable Equals Untransmittable
Jayleen K. L. Gunn et al.
AIDS AND BEHAVIOR (2021)
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E. Sax et al.
CLINICAL INFECTIOUS DISEASES (2020)
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen
Lucia Taramasso et al.
AIDS (2020)
Weight gain and integrase inhibitors
Allison Ross Eckard et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2020)
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG) plus F/TAF or DTG plus F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
Rima K. Acosta et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017
Mario Gomez et al.
INFECTION (2019)
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Hans-Juergen Stellbrink et al.
LANCET HIV (2019)
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
David A. Wohl et al.
LANCET HIV (2019)
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
Kristen Andreatta et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
Cissy Kityo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
David R. Bakal et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Jean-Michel Molina et al.
LANCET HIV (2018)
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Eric S. Daar et al.
LANCET HIV (2018)
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul E. Sax et al.
LANCET (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant et al.
LANCET (2017)
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Paul E. Sax et al.
LANCET HIV (2017)
The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
Jose R. Santos et al.
CLINICAL INFECTIOUS DISEASES (2015)
Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 Trial
Jean-Jacques Parienti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis
J. Troy Grennan et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy:: frequency, predictors and outcome
Pilar Garcia-Gasco et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Share Paper
